Pfizer Presents: Inclusive Research, More Equitable Medicine
The COVID-19 pandemic forced the world to grapple with a long-standing truth: that poor diversity in early and late stage medical research remains a major threat to health equity. Overcoming barriers and challenges to fair representation in research and development will not happen overnight, nor can it be achieved by a single institution. In order to pioneer lasting and sustainable changes in the way we conduct R&D, pharmaceutical companies and the broader research, medical, and patient communities need to come together—not only to assess current practices, but also to identify and address drivers of disparity. How can we apply the recent lessons of scientific innovations discovered in the pandemic to advance health equity?